VolitionRx Limited Moves Forward with $500,000 Cash Pre-Payment on Convertible Note
In a notable development, VolitionRx Limited, a prominent player in the field of epigenetics, has recently disclosed its decision to make a partial cash pre-payment of $500,000 on its convertible promissory note, originally issued for $2.4 million. This strategic financial move, which is part of a broader effort to strengthen its balance sheet, reduces the outstanding principal to approximately $706,667. This latest prepayment brings the total debt reduction across two notes to over $5 million since June 30, 2026, showcasing Volition's ongoing commitment to improving its financial stability.
The convertible note in question was issued to Lind Global Asset Management XII LLC and was dated January 15, 2026. Alongside this pre-payment, Volition engaged in an agreement with Lind to halt the exercise of their conversion rights until January 2027, contingent on the company's share price reaching or surpassing $0.275. Additionally, the required monthly repayments due in November and December 2026 have been deferred, allowing Volition to maintain a stronger cash position in the immediate future.
Commenting on this agreement, Volition's Chief Executive Officer, Cameron Reynolds, expressed gratitude for Lind's continued partnership and flexibility. 'We are very pleased to prepay a significant portion of the outstanding balance well ahead of schedule. With this prepayment, we have extinguished over $5 million across both notes since June 30th,' he stated. Reynolds further emphasized that enhancing Volition's financial position is a top priority, which also aligns with their goal of maximizing shareholder value through debt and expense reduction.
VolitionRx Limited is primarily focused on advancing the science of epigenetics. The company strives to foster better health outcomes for both people and animals suffering from serious diseases through earlier detection and effective monitoring of these illnesses. Leveraging its innovative research, Volition is developing and commercializing user-friendly and cost-effective blood tests aimed at detecting a range of diseases, including certain cancers and infections associated with NETosis like sepsis.
The importance of early detection and monitoring cannot be overstated as it has the potential to significantly prolong patients' lives and enhance their quality of living. As of now, VolitionRx remains committed to its mission, seeking to provide accessible solutions to urgent health challenges while steadily improving its financial stability. The focus on minimizing debt and reducing expenses demonstrates their proactive measures in navigating the complexities of the biotechnology landscape.
Looking ahead, VolitionRx continues to execute its strategic plans and remains vigilant in its pursuit of financial optimization and responsible growth. As evident from their recent activities and statements, the company is poised to address any challenges while unlocking further potential in the epigenetics market. Investors and stakeholders can closely monitor Volition’s progress as it advances its agenda and strives to meet its financial objectives in the forthcoming periods.
The convertible note in question was issued to Lind Global Asset Management XII LLC and was dated January 15, 2026. Alongside this pre-payment, Volition engaged in an agreement with Lind to halt the exercise of their conversion rights until January 2027, contingent on the company's share price reaching or surpassing $0.275. Additionally, the required monthly repayments due in November and December 2026 have been deferred, allowing Volition to maintain a stronger cash position in the immediate future.
Commenting on this agreement, Volition's Chief Executive Officer, Cameron Reynolds, expressed gratitude for Lind's continued partnership and flexibility. 'We are very pleased to prepay a significant portion of the outstanding balance well ahead of schedule. With this prepayment, we have extinguished over $5 million across both notes since June 30th,' he stated. Reynolds further emphasized that enhancing Volition's financial position is a top priority, which also aligns with their goal of maximizing shareholder value through debt and expense reduction.
VolitionRx Limited is primarily focused on advancing the science of epigenetics. The company strives to foster better health outcomes for both people and animals suffering from serious diseases through earlier detection and effective monitoring of these illnesses. Leveraging its innovative research, Volition is developing and commercializing user-friendly and cost-effective blood tests aimed at detecting a range of diseases, including certain cancers and infections associated with NETosis like sepsis.
The importance of early detection and monitoring cannot be overstated as it has the potential to significantly prolong patients' lives and enhance their quality of living. As of now, VolitionRx remains committed to its mission, seeking to provide accessible solutions to urgent health challenges while steadily improving its financial stability. The focus on minimizing debt and reducing expenses demonstrates their proactive measures in navigating the complexities of the biotechnology landscape.
Looking ahead, VolitionRx continues to execute its strategic plans and remains vigilant in its pursuit of financial optimization and responsible growth. As evident from their recent activities and statements, the company is poised to address any challenges while unlocking further potential in the epigenetics market. Investors and stakeholders can closely monitor Volition’s progress as it advances its agenda and strives to meet its financial objectives in the forthcoming periods.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.